Close Menu

digital PCR

NEW YORK (GenomeWeb News) – RainDance Technologies said today that it has closed a $20 million Series E financing round and that Myriad Genetics has joined as a new strategic equity investor.

Through its planned $13.6 billion acquisition of Life Technologies announced this week, Thermo Fisher Scientific stands to become the market leader in quantitative, real-time PCR research tools and reagents and DNA-based forensics and human identification.

Researchers from Italy's University of Genoa and other institutions have produced unpublished early data suggesting that digital PCR assays run on Life Technologies' recently launched QuantStudio 3D platform may be useful in measuring HER2 copy number in borderline-amplified breast cancer

Star Array, a spinout of Singapore's Nanyang Technological University, has developed a microfluidic liquid-phase nucleic acid purification chip that can selectively isolate DNA or RNA from low numbers of cells in minute sample volumes, and subsequently PCR amplify the purified nu

Bio-Rad this week reported record revenues of $204.2 million for its Life Sciences segment in the fourth quarter driven by strong sales of nucleic acid amplification reagents, process media, and sales of its QX100 digital PCR system and associated products, company executives said.

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said after the close of the market on Tuesday that fourth-quarter revenues improved 4 percent year over year as the firm beat the average analyst estimate on the top and bottom lines.

It has been nearly a year since RainDance Technologies officially "launched" its digital PCR platform, RainDrop, by recruiting researchers to be part of an early-access program.

Monoquant, an Australian company spun out of Flinders University to commercialize molecular methods to monitor minimal residual disease in blood cancers, has developed a PCR-based DNA assay that can routinely detect one cancerous cell in 10 million normal cells in chronic myeloid

Life Technologies has received CE IVD marking for its Applied Biosystems QuantStudio Dx platform and launched the instrument in Europe.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.